Drugs / SH3051
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04423380 | May 2020 → Mar 2021 | neoplasm | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SH3051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04423380 ↗ |
| Action | Inhibit | “a small molecule inhibitor of type I transforming growth factor-β(TGF-β) receptor serine/threonine kinase” NCT04423380 ↗ |
| Modality | Small molecule | “a small molecule inhibitor of type I transforming growth factor-β(TGF-β) receptor serine/threonine kinase” NCT04423380 ↗ |
| Route | Oral | “Starting dose 20mg,oral administered twice daily” NCT04423380 ↗ |